



Upregulation of PD-L1 expression in breast cancer cells through the formation of 3D multicellular cancer aggregates under different chemical and mechanical conditions

Shohreh Azadi^{a,b}, Hamidreza Aboulkheyr Es^a, Sajad Razavi Bazaz^a, Jean Paul Thiery^c, Mohsen Asadnia^b, Majid Ebrahimi Warkiani^{a,d,*}

^a School of Biomedical Engineering, University of Technology Sydney, Sydney, New South Wales 2007, Australia

^b School of Engineering, Macquarie University, Sydney 2109, Australia

^c Inserm Unit 1186, Comprehensive Cancer Center, Institut Gustave Roussy, Villejuif, France

^d Institute of Molecular Medicine, Sechenov University, Moscow 119991, Russia

ARTICLE INFO

Keywords:

EGFR
Substrate stiffness
Immunotherapy
Cetuximab
PD-L1

ABSTRACT

Expression of programmed death-ligand 1 (PD-L1) in cancer cells plays an important role in cancer-immune cell interaction. The emerging evidence suggests regulation of PD-L1 expression by several tumor microenvironmental cues. However, the association of PD-L1 expression with chemical and mechanical features of the tumor microenvironment, specifically epidermal growth factor receptor (EGFR) signaling and matrix stiffness, remains elusive. Herein, we determine whether EGFR targeting and substrate stiffness affect the regulation of PD-L1 expression. Breast carcinoma cell lines, MCF7 and MDA-MB-231, were cultured under different conditions targeting EGFR and exposing cells to distinct substrate stiffness to evaluate PD-L1 expression. Furthermore, the ability to form aggregates in short-term culture of breast carcinoma cells and its effect on expression level of PD-L1 was probed. Our results indicated that PD-L1 expression was altered in response to both EGFR inhibition and substrate stiffness. Additionally, a positive association between the formation of multicellular aggregates and PD-L1 expression was observed. MDA-MB-231 cells expressed the highest PD-L1 level on a stiff substrate, while inhibition of EGFR reduced expression of PD-L1. The results suggested that both physical and chemical features of tumor microenvironment regulate PD-L1 expression through alteration of tumor aggregate formation potential. In line with these results, the in-silico study highlighted a positive correlation between PD-L1 expression, EGFR signaling, epithelial to mesenchymal transition related transcription factors (EMT-TFs) and stemness markers in metastatic breast cancer. These findings improve our understanding of regulation of PD-L1 expression by tumor microenvironment leading to evasion of tumor cells from the immune system.

1. Introduction

It is broadly understood that the tumor microenvironment (TME) and its interplay with cancer cells play a crucial role in tumor initiation, progression, metastasis, and drug response [1,2]. A large number of studies highlighted the importance of non-cellular features of TME including extracellular matrix (ECM) and its stiffness in the induction of metastasis and drug resistance in various solid tumors [3–6]. The physical and chemical characteristics of TME can control the behavior and function of cancer cells [1,7,8]. Mechanical characteristics of TME changes during cancer progression expose tumor cells to different mechanical signals [9]. Variation of TME stiffness induced by cellular and non-cellular components is recognized as a pro-tumorigenic factor

[10–12]. Activation of various oncogenic signaling pathways through the cellular and physical properties of TME has been reported previously, resulting in enhancing hypoxia, invasiveness, stemness and immune-escaping capability of cancer cells [13,14].

During the past decade, immunotherapy has witnessed a revolution in cancer therapy with the development of immune checkpoint inhibitors, monoclonal antibodies against cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed cell death protein-1 (PD-1) or their ligands, including PD-1 ligand 1 (PD-L1) [15]. Emerging evidence highlighted roles of TME and ECM remodeling in regulating the cancer-immunity cycle [15–17]. However, the contribution of the ECM remodeling in shaping the immune microenvironment of the tumor is only beginning to be studied. Mechanical features of TME are

* Corresponding author at: School of Biomedical Engineering, University Technology Sydney, Sydney, New South Wales 2007, Australia.

E-mail address: majid.Warkiani@uts.edu.au (M. Ebrahimi Warkiani).

<https://doi.org/10.1016/j.bbamcr.2019.118526>

Received 4 April 2019; Received in revised form 20 July 2019; Accepted 4 August 2019

Available online 06 August 2019

0167-4889/ © 2019 Elsevier B.V. All rights reserved.

increasingly recognized as crucial factors in immune cell trafficking, activation and immunological synapse formation [18]. The density of ECM and basement membrane composition are regulated by stromal matrix components and plays a crucial role in immune cell migration, spatial distribution, and activation of immune-escaping features of cancer cells [15,17,19]. Additionally, numerous growth factors secreted by tumor-supportive cells in TME can enhance the immune-suppression capability of TME and immune-escaping potential of cancer cells. Recently several studies highlighted immune-modulatory effects and positive association of activation of epidermal growth factor receptor (EGFR) signaling with PD-L1 expression in TME [20,21]. However, the association between matrix stiffness and EGFR on the expression of PD-L1 has not been elucidated.

There is a growing interest in the three-dimensional culture of cancer cells through the formation of 3D multicellular aggregates. Cellular aggregates display a variety of features which could better mimic the tumor microenvironment [22,23]. An increasing number of studies demonstrated that the formation of tumor spheroids and cell aggregates could modulate numerous signaling pathways including stemness-related pathways [24–26]. Despite these studies, it is not yet been established whether the formation of cell aggregates can regulate the PD-L1 expression. This study was designed to determine whether the chemical and mechanical features of TME regulate the multicellular cancer aggregate (MCA) formation ability and PD-L1 expression in human breast cancer cells. Our findings postulated regulation of PD-L1 expression by EGFR signaling pathway, substrate stiffness, and MCA formation.

2. Materials and methods

2.1. Cell culture

Cells of human breast cancer cell lines MCF7 (non-invasive) and MDA-MB-231 (highly invasive) were acquired from the University of Technology Sydney (UTS), Faculty of Science. The cells were maintained in the RPMI culture medium (ThermoFisher Scientific, USA) containing 10% fetal bovine serum (FBS) (ThermoFisher Scientific, USA) and supplemented with 1% L-glutamate (ThermoFisher Scientific, USA) in an atmosphere of 5% CO₂ and 95% air at 37 °C. Both cell lines were cultured in five different study groups as illustrated in Fig. 1, two as chemical groups and three as mechanical groups that referred to as non-treated, Cetuximab treated, stiff, semi-soft and soft substrates, respectively. Fig. 1 presents a schematic illustration of workflow that will be described below.

2.2. Substrate preparation and characterization

To examine the effect of substrate stiffness on PD-L1 expression and the MCA formation ability of cancer cells, polydimethylsiloxane (PDMS) substrates with different stiffness were utilized. These substrates were prepared by mixing the silicone elastomer with the curing agent (Sylgard 184, Dow Corning, USA). Varying the ratio of elastomer to the curing agent allowed us to achieve PDMS substrates with different elastic modulus with negligible changes in other chemical and physical properties [27,28]. Here we fabricated PDMS substrates by mixing silicone elastomer with the curing agent at a ratio of 10:1 and 50:1 and 75:1, to obtain stiff, semi-soft and soft substrates, respectively. Then, the mixture was degassed to expel bubbles and cured for 24 h at 70 °C. To ensure cell-substrate adhesion, synthesized substrates were treated via air plasma by a low-frequency plasma generator (230 V, Harrick Plasma, USA) at 30 W for 3 min, sterilized by UV for 30 min followed by coating with a thin layer of fibronectin (10 µg/ml, Sigma-Aldrich, USA). Finally, the substrates were rinsed with PBS to remove excess protein and were immediately employed for cell seeding.

The substrate elasticity was measured by atomic force microscopy (AFM) indentation technique using a Nanowizard II atomic force

microscope (JPK Instruments, Germany). The indentation was performed with V-shaped silicon nitride cantilever with a spring constant of 0.046 N/m (HYDRA6V-200NG, APPNANO, USA), at an approach velocity of 3 µm/s and a maximum indentation depth of 0.5 µm. For each substrate, three samples were prepared, and 70 to 100 force-displacement curves were recorded for each sample. The average Young's moduli were calculated from at least 150–200 curves for each substrate (from three independent experiments) and reported as mean ± SD. Briefly, in this technique, a flexible cantilever with a sharp tip indented the surface. During the indentation, the substrate-cantilever interaction led to a vertical deflection of the cantilever that was converted to the force and recorded against the indentation. The resulting force-indentation curve was used to obtain Young's modulus according to the modified Hertz model for a quadrilateral pyramid tip (Eq. (1)) [29].

$$F(\delta) = \frac{1.49E_{\text{sub}}\tan\alpha}{2(1-\sin^2\alpha)}\delta^2 \quad (1)$$

where, F is the force, δ is the indentation depth, and α is the half angle of pyramid tip which was set to 17.5°. The Poisson's ratio of substrates (ν_{sub}) was assumed to be 0.5 considering an incompressible material property for PDMS.

2.3. Anti-EGFR treatment

To assess the potential correlation between the PD-L1 protein expression with EGFR signaling and the MCA formation ability, the EGFR pathway was targeted by the anti-EGFR antibody Cetuximab (Merk, Germany). Cetuximab blocked EGFR through its binding to the extracellular domain of EGFR preventing receptor dimerization [30]. For immunostaining and ELISA, breast cancer cells were exposed to a culture medium supplemented with 10 µg/ml Cetuximab for 48 h. For MCA formation experiments, breast cancer cells were treated with the mentioned concentration of Cetuximab during the MCA formation process. The chosen concentration was below the reported peak plasma concentration of this drug [30,31].

2.4. Evaluation of the PD-L1 expression

The PD-L1 expression of breast cancer cell lines was analyzed among different chemical and mechanical groups by immunofluorescence staining and enzyme-linked immunosorbent assay (ELISA). PD-L1 assessment was performed before and after formation of cellular aggregates.

2.4.1. Immunofluorescence staining of PD-L1

For PD-L1 immunostaining experiments, PDMS was spin-coated onto the glass slides at 2000 rpm for 30 s. Two types of breast cancer cells were cultured among five study groups. After 24 h, the cells were fixed and permeabilized for 10 min with chilled 100% methanol (SigmaAldrich, USA). The fixation was followed by three times washing with phosphate-buffer saline (PBS) solution (ThermoFisher Scientific, USA) and blocking with 1% bovine serum albumin (BSA) (ThermoFisher Scientific, USA) in PBS for 60 min. Then, the cells were incubated with a rabbit monoclonal anti-PD-L1 antibody (dilution 1:100, ab209960, Abcam, USA) in PBS containing 1% BSA for overnight at 4 °C. Finally, the samples were washed and further incubated with 4,6-diamino-2-phenylindole (DAPI) (dilution 1:1000, D9542; SigmaAldrich, USA) for 5 min at room temperature. An inverted fluorescence microscope (Olympus IX71, USA) was utilized to capture the immunofluorescence images.

2.4.2. Measuring PD-L1 concentration using ELISA

The PD-L1 concentration was assessed among chemically and mechanically treated groups of the two breast carcinoma cell lines using quantitative ELISA kit (ab214565, Abcam, USA). ELISA was performed according to the manufacturer's instruction. First, cells were seeded at




Fig. 1. Schematic illustration of the workflow. Breast cancer cells were cultured among chemical and mechanical study groups and assessed for PD-L1 expression before and after formation of multicellular aggregates.

the concentration of 10^5 cells/ml on three PDMS substrates. The same number of cells was cultured in non-treated and Cetuximab-treated groups. After 48 h, the samples were extracted from the adherent cells and prepared according to the manufacturer's protocol. Briefly, the samples were added to the appropriate wells and incubated with the capture and detector antibodies for 1 h at room temperature, then washed with the washing buffer followed by incubation with 3,3',5,5'-tetramethylbenzidine (TMB) development solution and the stop solution. Finally, the optical density (OD) was recorded at 450 nm immediately after adding the stop solution. Eight standard samples with the pre-determined PD-L1 concentration were used to obtain a standard curve (data not shown). The standard curve was created by plotting the absorbance value for each standard concentration against the target protein concentration. This curve was fitted and employed to determine the concentration of PD-L1 protein in the samples. For each sample, three independent measurements were performed, and all the measurements were conducted in duplicate for statistical analysis.

2.5. MCA formation

2.5.1. Pre-treatment of the microwells before cell seeding

MCAs were formed using the microwell technique [23,32,33]. The 3D SpheroFilm™ microwell was obtained from Incyte Co. (Korea) with the inner diameter of 300 μ m and the well depth of 300 μ m. Each device consisted of 361 silicone elastomer microwells. To prepare the microwells for cell culturing, their surface was UV sterilized and pretreated with 100% ethanol (SigmaAldrich, USA) repeatedly pipetted to remove the air bubbles from the wells. Then the wells were washed three times with PBS by repeatedly pipetting and incubated with the cell culture medium overnight [34].

2.5.2. Cell seeding in the microwells

For each cell line, five SpheroFilm devices were used, two devices

for non-treated and Cetuximab-treated cells and three devices for stiff, semi-soft and soft groups. First, breast cancer cells were cultured on the three mentioned PDMS substrates for 24 h before introducing into the microwells. After removing the medium from the SpheroFilm devices, a total number of 1.4×10^6 breast cancer cells were distributed over the microwell surfaces of each group at the concentration of 2×10^5 cells/ml. After 15 min of cell seeding, the suspending cells were removed by aspiration, and fresh growth media was added. The medium was changed every day until the end of the MCA formation assay. For Cetuximab-treated group, the cells were exposed to the medium containing Cetuximab at the concentration of 10 μ g/ml.

2.5.3. Isolation of the MCA from the microwells

After two days of culturing in the microwells, multicellular breast cancer aggregates were dislodged by pipetting growth medium onto the microwells, repeatedly. MCAs with the size of above 100 μ m were obtained using a cell strainer with a pore size of 100 μ m. After adding the MCAs, the strainer was flipped, and the growth medium was added to the bottom surface of strainer to collect the MCAs. The isolated MCAs were transferred to the appropriate wells or slides for further assessments.

2.6. MCA characterization

To evaluate the MCA formation ability of breast cancer cells with the different expression of PD-L1, the MCAs were characterized by performing live and dead assay, counting the number and diameter of formed MCAs, assessment of PD-L1 expression and MCA spreading.

2.6.1. Cell viability of MCA

MCAs were labeled directly in 48-well plates using a Cellstain double staining kit (Sigma Aldrich, USA) according to the manufacturer's protocol. The viable cells were labeled with Calcein-AM which

stained the cytoplasm in green. Nuclei of the dead cells were labeled with propidium iodide in red. The MCAs were incubated in the assay solution (5 ml of PBS containing 10 μ L of Calcein-AM and 5 μ L of propidium iodide) in each well for 15 min at 37 °C. The live/dead fluorescence images were captured using an inverted fluorescence microscope (Olympus IX71, USA).

2.6.2. Measurement of MCAs number and diameter

The formed MCAs among different groups were imaged using an Olympus IX71 inverted microscope. The total number of MCAs was determined by adding 400 μ L of the final MCA suspension (4 ml) in 48-well plate. The average diameter of MCAs was also calculated by measuring the diameter of at least 40 MCAs in each group. ImageJ (NIH, Bethesda, MD) was employed for number and diameter measurements [35]. Most of the MCAs presented a spherical shape. For those had ellipsoid shape, the longest dimension was measured as the diameter.

2.6.3. Immunofluorescence staining of PD-L1

To assess the PD-L1 expression in MCAs, isolated MCAs were stained with anti-PD-L1 antibody. First, the MCAs were fixed with chilled 100% methanol for 10 min at -20 °C, then centrifuged at a speed of 1200 rpm for 5 min to remove methanol. The samples were washed with PBS followed by blocking with 1% BSA for 1 h at room temperature. Then the MCAs were stained with a rabbit monoclonal PD-L1 antibody by overnight incubation at 4 °C. Later, the samples were washed three times with PBS to remove the unbound antibody. Finally, the nuclei were stained with DAPI for 5 min and the images captured using an inverted fluorescent microscope.

2.7. MCAs spreading

Isolated MCAs were transferred to the 24-well plate and allowed to spread. The MCAs were monitored under a microscope to observe whether they attached to the surface. After the attachment of MCAs, the culture media was removed, and the fresh media added for the further cell aggregates cultivation and analysis. The PD-L1 expression of breast cancer cells in the spread MCAs was analyzed using the immunofluorescence staining of PD-L1 followed with measuring PD-L1 concentration by ELISA as described before.

To measure the PD-L1 concentration after formation of MCAs, first, MCAs were attached and spread for 24 h, then spread MCAs were dissociated using trypsin (SigmaAldrich, USA) and the number of cells counted among five study groups of MCF7 and MDA-MB-231 spread aggregates. Finally, the counted cells were transferred to a new well at the concentration of 10⁵ cells/ml and incubated for another 24 h. ELISA was performed according to the manufacturer's instruction, as mentioned before.

2.8. The TCGA data analysis

The genomic alterations, co-expression, and correlation studies were performed on data from The Cancer Genome Atlas (TCGA), PanCancer Atlas Breast cancer database using TCGAWorkflow package under R-Software (version 3.8) and cBioportal (www.cbioportal.org). The protein-protein interaction analysis was performed by STRING PPI package under Cytoscape software (version 3.7.0).

2.9. Statistics

The results of quantitative experiments were expressed as mean \pm SD. The statistical analysis was performed with Student *t*-test. **p*-Value < 0.05 was considered as a statistically significant and ***p*-value < 0.005 was considered as an extremely significant. Microscopic images are representative images from three independent experiments. All Immunofluorescence staining experiments were repeated three

times and three to five different sections were captured by fluorescent microscope for each sample. Data shown for the MCA diameter are the averages from at least 40 number of MCAs from three independent experiments. PD-L1 ELISA was conducted in three separate replicates as mentioned before.

3. Results

3.1. PDMS substrates elastic modulus

Three PDMS substrates with the different elastic moduli were achieved by controlling the ratio of polymer to the crosslinking agent. The elastic moduli of PDMS substrates with the ratio of 10:1, 50:1 and 75:1, were measured as 1.22 \pm 0.2 MPa, 32.38 \pm 2.2 kPa, and 5.10 \pm 0.4 kPa, respectively. These values cover the physiologically relevant elastic moduli of TME that are used to examine how the substrate rigidity affects the biological behavior of cancer cells [36,37]. As mentioned, these substrates are referred to as stiff, semi-soft and soft in this paper.

3.2. Expression of PD-L1 protein in breast cancer cells

First, we determined the expression of PD-L1 protein in two breast cancer cell lines among five groups of non-treated, CTX-treated, stiff, semi-soft, and soft. Fig. 2 exhibits the immunofluorescent images of PD-L1 and nucleus of breast cancer cells, which demonstrates that the degree of PD-L1 expression varies considerably among the study groups of breast cancer cells. Consistent with the findings in the previous literature [38], high expression of PD-L1 protein was observed in MDA-MB-231 cells (Fig. 2B) whereas, there was a low expression of PD-L1 protein in MCF7 cells (Fig. 2A). To calculate the percentage of MDA-MB-231 cells with positive expression of PD-L1, the number of cells with positive PD-L1 fluorescent signal was counted and compared to the total number of cells in each figure using ImageJ (NIH, Bethesda, MD) [35]. The final values were calculated by averaging between three independent experiments for each study group. Application of anti-EGFR antibody for 24 h significantly reduced the PD-L1 protein level in MDA-MB-231 cells from 92% \pm 3% positive cells to 35% \pm 6%, which revealed that the PD-L1 expression is positively related with the EGFR signaling. In addition, the effect of substrate stiffness on the PD-L1 expression was examined. The PD-L1 expression of MDA-MB-231 cells was affected not only by the chemical treatment but also by the substrate stiffness. Cancer cells on the stiff substrate expressed the most PD-L1 among three PDMS substrates with different rigidity. Substrate softening reduced the number of PD-L1 positive MDA-MB-231 cells from 74% \pm 5% for the stiff substrate to 50% \pm 6%, and 22% \pm 3% for the semi-soft and soft substrates, respectively.

3.3. Characterization of the breast tumor MCAs

In this paper, MCA formation was performed in microwells. We screened the MCA formation ability of two breast cancer cells in five study groups. For all groups, the single cell suspension was seeded into the microwells, and most of the cellular aggregates reached above 100 μ m after two days. The SpheroFilm device and MCA formation steps of two breast cancer cells are schematically illustrated in Fig. 3. Initially, cells settled in the bottom of microwells. After one day, the cells started to attach together and form cell aggregates. Later, on day 2, they formed denser 3D structures.

Initially, we examined the cell viability of MCAs and confirmed that both cell lines displayed > 95% viability by Calcein AM staining (Fig. 4A) in all groups of study. Due to the small size of MCAs (< 300 μ m), the necrotic core was not observed in any of them. Next, we examined whether the EGFR targeting and substrate stiffening involved in the MCAs formation. The total number of formed MCAs and their average diameter are shown in Fig. 4 (B and C). We observed a




Fig. 2. Regulation of PD-L1 expression by EGFR signaling and substrate stiffening. Representative immunofluorescent images of (A) MCF7 and (B) MDA-MB-231 cells cultured on non-treated, EGFR treated, stiff, semi-soft, and soft groups for 24 h, stained for PD-L1 (red) and nuclei (blue). Images were obtained using an inverted fluorescent microscope. Scale bar denotes 50 μ m and experiments were repeated three times.

considerable difference in the number and diameter across the formed aggregates. Although both breast cancer cells successfully formed MCAs, MDA-MB-231 cells were able to form more MCA with a larger size. The total number of formed aggregates in different groups of breast cancer cells has been displayed in Fig. 4, while Table 1 reports the number of single cells versus aggregates to establish an MCA titer. This titer was calculated by dividing the number of formed aggregates by the number of single cells added to the SpheroFilm device. Our results revealed that Cetuximab treatment resulted in the alteration of MCA formation ability of breast cancer cells. The treated cells decreased MCA formation ability in terms of number and diameter which suggests that MCA formation of cancer cells strongly depends on the EGFR activity ($*p < 0.005$). MCA titer decreased from 1/5384 and 1/5000 for MCF7 and MDA-MB-231 cells in control groups to 1/7000 and 1/10,000 in Cetuximab-treated groups, respectively.

Furthermore, the MCA formation ability of both cancer cells was altered with the substrate stiffening. MCF7 and MDA-MB-231 cells cultured on the stiff substrates revealed more ability for MCA formation compared with the softer substrates ($*p < 0.05$). Although both cell lines respond to the substrate stiffness, non-invasive MCF7 cells showed more sensitivity than invasive MDA-MB-231 cells. The MCA titer of 1/6086 and 1/4000 in the stiff groups of MCF7 and MDA-MB-231 cells decreased to 1/14000 and 1/7368 in the soft groups, respectively. These changes were accompanied by a decrease in the average diameter of MCF7 MCAs from $200 \pm 43 \mu\text{m}$ to $167 \pm 54 \mu\text{m}$ by substrate softening ($*p < 0.05$).

Next, we examined whether PD-L1 is involved in the MCA formation induced by the EGFR blocking and substrate stiffening. Fig. 5 provides

representative immunofluorescent images of cancer aggregates, which reveals that MCA formation increased PD-L1 expression of breast cancer cells in the EGFR-dependent and stiffness-dependent manner. Breast MCAs from both cell lines characterized with the lower expression of PD-L1 in the soft group compared with the stiff group as well as the Cetuximab-treated group compared with the non-treated group. These results suggest an upregulation of PD-L1 through the formation of MCA, which is mediated by chemical and mechanical factors.

3.4. Assessment of the PD-L1 expression in spread breast MCA

Next, we further investigated whether MCA formation affects PD-L1 expression. Since MCAs are the 3D structures of hundreds of cells, their PD-L1 immunostaining would not be adequate to confirm the induction of PD-L1 expression by MCA formation. Therefore, we examined the PD-L1 expression of MCAs after spreading for 24 h to permit the formation of a cell monolayer. Fig. 6A, and B illustrate the spreading of cellular aggregates and formation of the monolayer, which consisted of those cancer cells that were successfully involved in the MCA formation. Additionally, to provide some quantitation, mean fluorescent intensity (MFI) of MCF7 and MDA-MB-231 cells was analyzed using ImageJ from at least three independent imaging experiments for each group of study and has been reported in Fig. 6C. MCF7 cells showed an increased PD-L1 expression not only in the MCAs but also in the spread aggregates, which demonstrates induction of the PD-L1 expression by the MCA formation. Quantification of fluorescent intensity in Fig. 6C revealed a positive correlation between the substrate stiffness and the PD-L1 expression of MCF7 cells ($*p < 0.05$). As shown before, the




Fig. 3. Schematic of the SpheroFilm utilized to generate multicellular cancer aggregates (MCAs) and representative images of the MCA formation of breast cancer cells. Scale bar is 100 μ m. (I) Side view of the SpheroFilm contains 361 microwells with a diameter of 300 μ m, and depth of 300 μ m (II) Breast cancer cells were seeded into the microwells (day 0) among five study groups of non-treated, CTX-treated, stiff, semi-soft, and soft (III) The cancer cells grouped together to form cell aggregates after 1 day (IV) Cell aggregates formed dense 3D spherical structures after 2 days (V) MCAs were isolated from SpheroFilm and strained with a 100 μ m pore filter.

spread MCAs of MDA-MB-231 cells showed that the expression of PD-L1 is closely related to the EGFR activity. Moreover, the PD-L1 staining of MDA-MB-231 cells in Fig. 6 indicates the PD-L1 expression in the stiff substrate is more than the soft substrate but not the semi-soft substrate. This result is consistent with the concentration of PD-L1 from ELISA in Fig. 7B which confirms that PD-L1 concentrations in the stiff and semi-soft groups of MDA-MB-231 cells are very close to each other. Moreover, ELISA before MCA formation (Fig. 7A) demonstrated similar results for the stiff and semi-soft groups of MDA-MB-231 cells. These findings suggest that although MDA-MB-231 cells exhibited a substrate-dependent expression of PD-L1, they are more sensitive to the substrate stiffness in the range of 5 to 35 kPa which are related to semi-soft and soft substrates in this study.

To confirm the results of PD-L1 staining in Fig. 2, ELISA was employed to measure the PD-L1 concentration. In agreement with the PD-L1 staining results before multicellular formation, the PD-L1 concentration of MCF7 cells was measured below 30 pg/ml for all study groups (Fig. 7A). The PD-L1 protein concentration of invasive breast cancer cells (MDA-MB-231) was significantly reduced from 1898 ± 62 pg/ml in the non-treated group to 1341.6 ± 110 pg/ml after EGFR targeting (* $p < 0.05$). Similarly, the PD-L1 concentration of MDA-MB-231 cells grown on the soft substrate was significantly lower than those grown on the stiff substrate (* $p < 0.05$). The values of 1620 ± 29 pg/ml, 1500 ± 49 pg/ml, and 1000 ± 66 pg/ml were obtained for stiff, semi-soft, and soft substrates, respectively (Fig. 7A). The above-mentioned results suggest that PD-L1 expression could be mediated by chemical and mechanical tumor microenvironmental cues.

To further confirm these results, the PD-L1 staining of spread aggregates was accompanied with measuring of PD-L1 concentration using ELISA (Fig. 7B). Among the five study groups of MCF7, we found the highest PD-L1 level in the non-treated group. In line with the data

assessed by the immunofluorescent microscopy, MCF7 cells appeared as PD-L1 positive after MCA formation. Furthermore, the PD-L1 concentration of spread MCAs of MCF7 reached 214 ± 28 pg/ml, 153 ± 19 pg/ml and 151 ± 24 pg/ml in stiff, semi-soft, and soft groups, respectively. In contrast, MDA-MB-231 cells did not exhibit a significant change in the PD-L1 concentration after MCA formation. In agreement with the previous results, spread aggregates of MDA-MB-231 cells exhibited noticeable PD-L1 expression mediated by EGFR blocking and substrate stiffening, so that Cetuximab treatment caused a decrease in PD-L1 expression in these cells.

3.5. The TCGA data analysis

The genomic alteration analysis shows that the basal subtype of breast cancer exhibits the highest expression and amplification of EGFR, PD-L1 (CD274) and PROM-1 compared to other subtypes (Fig. 8A). Furthermore, positive correlation and co-expression between PD-L1 with EGFR, CD44 and epithelial to mesenchymal transition-related transcription factors (EMT-TFs) SNAIL1, ZEB1 and TWIST1 were observed (Fig. 8B). In line with these results, the protein-protein interaction analysis illustrated a direct interaction between PD-L1 and EGFR with stemness-related genes and EMT-TFs (Fig. 8C).

4. Discussion

It is well established that the expression of PD-L1 plays an important role in cancer cell-mediated immune response. Expression of PD-L1 has been found in 5–40% tumor cells, helping tumor cells to escape from the immune elimination [39]. PD-L1 is one of the key molecular pathways used by tumor cells to engage T cell immune checkpoints. PD-L1 expressed on the surface of tumor cells binds to PD1, which is




Fig. 4. MCA characterization. (A) Live and dead assay reveals excellent viability of 3D MCAs of MCF7 and MDA-MB-231 cells among five chemical and mechanical treated groups. The live cells were stained with Calcein AM (green), and the dead cells were stained with PI (red), as described in materials and methods. Arrows show some of dead cells. The images were obtained by fluorescent microscopy with a scale bar of 100 μm. (B and C) Number and diameter of MCAs with (B) MCF7 and (C) MDA-MB-231 cells. The number of MCAs has been represented as the mean ± SD of three independent experiments. The mean diameter of MCAs has been represented as the mean ± SD of at least 40 MCAs in each group.

Table 1

Aggregate formation ability of breast cancer cells in different chemical and mechanical groups. Values display MCA titer which is the number of formed MCAs per number of single cells.

Group	Cell	
	MCF7	MDA-MB-231
Non-treated	1/5384	1/5000
Treated	1/7000	1/10,000
Stiff	1/6086	1/4000
Semi-soft	1/5833	1/6666
Soft	1/14,000	1/7368

expressed by activated T cells, leading to bypassing immune checkpoints to evade immune recognition and protects tumor cells from T cell-mediated killing [40].

The cellular expression of PD-L1 could be affected by different chemical and mechanical factors of tumor microenvironment. Hence, identifying cellular and molecular mechanisms driving PD-L1 expression is crucial for the successful prediction of response to the PD-L1 targeted therapy. In this study, the effect of EGFR signaling and substrate stiffness, two important tumor microenvironmental factors on

PD-L1 expression of breast cancer cells, was investigated. Further, we evaluated whether MCA formation of breast cancer cells could contribute to enhancing PD-L1 expression. It has been demonstrated that different cancer cell types express different levels of PD-L1 that could be associated with their invasive potential [41]. Kim et al. indicated that metastatic lung cancers express more PD-L1 as compared to the primary tumor [42]. A similar result was observed for breast cancer cells [38,41]. Our finding also confirmed high PD-L1 expression of invasive MDA-MB-231 cells, while non-invasive MCF7 cells display a modest level of PD-L1 (*p < 0.05).

Moreover, PD-L1 level of MDA-MB-231 cells is modulated by EGFR signaling and substrate stiffening. There are several studies which evaluated the effect of substrate stiffness on the cellular behavior of cancer cells [43,44]. They cultured different types of cells usually on PDMS and Polyacrylamide gels with different elastic moduli in the range of kPa to MPa [36,37,45]. In this study, choosing three different ratios of elastomer to curing agents for PDMS substrates resulted in the stiffness of 5 kPa to 1 MPa while the curing agent ratio was enough to achieve a complete polymerization process of PDMS. This range of stiffness is consistent with previously published data [46] and close to tumor stromal microenvironment [37,47]. They reached the conclusion that cancer cells respond to the substrate rigidity by changing protein





Fig. 5. Role of the MCA formation in the PD-L1 expression of breast cancer cells. Representative bright field and immunofluorescence images of (A) MCF7 and (B) MDA-MB-231 MCAs in five study groups of non-treated, CTX-treated, stiff, semi-soft, and soft, stained for PD-L1 (red) and nuclei (blue). Images were obtained using a fluorescent microscope, and scale bar denotes 50 μ m and experiments were repeated three times.

expression, proliferation, migration and differentiation ability. Most recently, Miyazawa et al. probed the effect of substrate stiffness on the PD-L1 expression of lung cancer cells [48]. They demonstrated that substrate stiffening enhanced the PD-L1 level via actin-dependent mechanisms. Here, we investigated such a relationship by culturing breast cancer cells on stiff, semi-soft and soft PDMS substrates and demonstrated the relation between substrate stiffness and PD-L1 expression.

The association between EGFR and PD-L1 signaling pathways plays an important role in cancer targeted therapy and is gaining much more interest in recent years. Several studies evidenced a positive correlation between EGFR activity and PD-L1 expression [49,50]. MDA-MB-231 cells have been shown to express a high level of EGFR, which render them as a suitable target for anti-EGFR treatment [51,52]. EGFR is

involved in the modulation of PD-L1 expression through AKT and STAT3 downstream signaling pathways [53,54]. Regarding the correlation between these two important signaling pathways, much more attention has been paid for a combined targeting of EGFR and PD-L1 in recent years [55]. Our results indicated that EGFR-positive MDA-MB-231 cells expressed a high level of PD-L1, while EGFR-negative MCF7 cells did not show a significant level of PD-L1, which is in good agreement with previously published papers [38,41]. Moreover, Cetuximab treatment of MDA-MB-231 cells was accompanied with a noticeable reduction of PD-L1, which further confirmed the relationship between PD-L1 expression and EGFR signaling pathway.

In line with these results, few preclinical studies on patients with advanced lung adenocarcinoma highlighted that acquired resistance to



(caption on next page)

Fig. 6. PD-L1 expression of spread MCAs of breast cancer cells as a function of EGFR activity and substrate stiffness. Representative bright field and immunofluorescence images of (A) MCF7 and (B) MDA-MB-231 MCAs in five study groups which were stained for PD-L1 (red) and nuclei (blue). Images were obtained using a fluorescent microscope. Scale bar represents 100 μ m and experiments were repeated three times. (C) Mean fluorescent intensity was analyzed using ImageJ. The values are mean \pm SD of three independent experiments. *Significantly different between the groups ($p < 0.05$) and ** ($p < 0.005$).




Fig. 7. Comparison of protein concentration of PD-L1 in the chemical and mechanical groups, before and after formation of MCAs. The PD-L1 concentration of two breast cancer cell lines, MCF7 and MDA-MB-231 cells was measured by ELISA among five study groups of non-treated, Cetuximab treated, stiff, semi-soft, and soft substrates (A) before and (B) after MCA formation. The values are mean \pm SD of three independent experiments with duplicate measurements for each. *Significantly different between the groups ($p < 0.05$) and ** ($p < 0.005$).

EGFR-TKIs can amplify the expression of PD-L1 and enhance immune escape in EGFR mutant lung adenocarcinoma in which targeting PD-L1 restored sensitivity of tumor cells to lymphocytes [56]. Interestingly, in a clinical study conducted by Lee and colleagues in EGFR-mutated lung adenocarcinomas patients treated with first-line EGFR-TKIs, the high tumor proportion score of PD-L1 negatively associated with the treatment response rate and the patient outcome, compared to EGFR-TKI sensitive tumor cells [57]. These results not only highlight a positive association between EGFR and PD-L1 expression, but also indicate the potential application of PD-L1 expression as a prognostic biomarker for patients with EGFR mutation.

There are various factors that could be influential in PD-L1 expression. It has been shown that PD-L1 contributes to cancer stemness, EMT and tumor invasion, albeit not focusing on EMT and stemness [50,58,59]. Noman et al. demonstrated that PD-L1 is upregulated through EMT activation of breast cancer cells by involving ZEB-1 and miR-200 [60]. Here, by analyzing data of invasive breast cancers from The Cancer Genome Atlas (TCGA) and protein-protein interaction, we illustrated a possible correlation between PD-L1 with EGFR, stemness-related genes, and EMT-TFs (Fig. 8). In line with these results, Malta et al. reported a positive association between immune microenvironment content, PD-L1 levels and stemness features in breast cancer [59]. Additionally, the high expression of PD-L1 in CD44⁺ breast cancer cells and its role in maintaining stemness factors including OCT-4A, Nanog and BMI1 have been reported [58,61].

In this study, two approaches, substrate stiffness and EGFR targeting, were used to change the PD-L1 expression of breast cancer cells. It has been demonstrated that both approaches could activate EMT and alter stemness factors [62–64]. Abhold et al. reported a reduction of mesenchymal markers by EGFR targeting [63] while You et al. probed an enhancement of stemness markers by substrate stiffening [62]. Regarding these studies, it can be concluded that both EGFR signaling and substrate stiffening could modulate the PD-L1 expression through the


mediation of EMT and stemness.

Our results indicated the successful formation of breast MCAs in both cell lines among five study groups. However, noticeable differences were observed in the MCA formation ability of breast cancer cells in terms of MCA diameter and number. The effect of substrate stiffness on the various cellular behaviors has been investigated, while there is not any report addressing the effect of substrate stiffening on the MCA formation. For the first time, to our knowledge, we showed that cancer cells derived from the stiff substrate had a greater ability to form MCA. Furthermore, the MCA formation was influenced not only with the substrate stiffness but also with the EGFR activity. Cetuximab-treated MCF7 and MDA-MB-231 cells indicated a decrease of 23% and 50% respectively in the number of formed MCAs compared to non-treated cells, respectively. The average diameter of MCAs also decreased from the stiff to the soft substrate. Moreover, analyzing the number and diameter of breast cancer MCA revealed that their aggregate formation ability positively correlated with the PD-L1 expression level.


In this study, MCAs were formed to investigate how cancer aggregate formation could alter the PD-L1 expression of breast cancer cells. Overall, the assessment of PD-L1 level by immunostaining as well as ELISA indicated that firstly, MCAs derived from cells grown on the stiff substrate showed a higher level of PD-L1 among the three PDMS substrates, secondly, EGFR targeting decreased the PD-L1 level not only in the cancer cell monolayer but also in MCAs, and thirdly, the MCA formation considerably enhanced PD-L1 expression level of MCF7 cells.

Stemness markers could be affected by different mechanisms through spheroidogenesis of cancer cells [25]. Chen et al. reported that spheroid formation led to overexpression of stemness-related genes [65]. Moreover, it has been shown that formation of MCA could guide EMT shifting and collective cell invasion through Snail1, Vimentin, and E-cadherin gene expression alterations [66]. Furthermore, as discussed before, stemness markers and EMT process also correlate to PD-L1 expression. Our finding also demonstrated the association between MCA


(A)



(B)



(C)



(caption on next page)

Fig. 8. Genomic and protein-protein interaction analysis of PD-L1. (A) The TCGA Pan-Breast Cancer Atlas genomic analysis. The oncoprint data shows amplification and up-regulation of PD-L1, EGFR, and PROM-1 in Basal subtype of breast cancer compared to other subtypes. (B) Co-expression and correlation analysis of PD-L1 expression with EGFR, CD44, and core EMT-TFs (C) protein-protein network interaction between PD-L1, EGFR and panel of candidate stemness genes and EMT-TFs in breast cancer.

formation and PD-L1 expression. Taken together, our results suggest that the formation of MCAs could modulate the PD-L1 expression of MCF7 cells through the possible mediation of stemness markers and/or EMT factors.

Molecular targeted therapy (e.g., EGFR and Her2 inhibitors) and immunotherapy (e.g., PD1/PD-L1 inhibitors) are two of the most important approaches in cancer treatment. Unlike molecular targeted therapy, the prediction of response to immunotherapy faces more challenges. Although PD-L1 expression is widely used as a predictive biomarker to immunotherapy, to date, many immunotherapy treatments have demonstrated a low efficacy in most patients [67]. Our results indicate that even for PD-L1-negative cancer cells such as MCF7, PD-L1 expression could be altered by different cellular and molecular mechanisms, and in such a situation different therapeutic approaches should be considered. Therefore, successful prediction of response to immunotherapy, specifically PD-L1 targeting, requires much more experimentation in 2D and 3D microenvironments, under various chemical and mechanical conditions. Moreover, the correlation between EGFR and PD-L1 supports the approach of combination therapy as a more effective strategy to modulate cancer cell-immune cell interactions.

5. Conclusion

In summary, we showed that PD-L1 expression, an important biomarker of immunotherapy, is modulated by both substrate stiffness and EGFR activity. Further, we demonstrated that the PD-L1 expression level is associated with the formation of cellular aggregates. So, even for those cancer cells with a low level of PD-L1, the possible changes in the cancer cell-immune cell interaction should be considered. Overall, to achieve a successful prediction of response to immunotherapy, different influential chemical and mechanical factors should be examined. The evidence from this study has gone some way toward enhancing our understanding of factors which modulate the PD-L1 expression. Our findings suggest two possible relationships, firstly between the MCA formation and PD-L1 expression, and secondly, between PD-L1 expression and stemness/EMT markers which are involved in cancer progression. Further experiments will be required to determine which mechanisms underlie the regulation of PD-L1 expression during the EMT and acquired stemness features.

Transparency document

The [Transparency document](#) associated with this article can be found, in online version.

Declaration of competing interest

No potential conflict of interest was reported by the authors.

Acknowledgements

This work was supported by National Health and Medical Research Council (NHMRC) APP1143377.

References

- [1] D.A. Senthane, A. Rowe, N.E. Thomford, H. Shipanga, D. Munro, M.A. Al Mazeedi, H.A. Almazyadi, K. Kallmeyer, C. Dandara, M.S. Pepper, The role of tumor microenvironment in chemoresistance: to survive, keep your enemies closer, *Int. J. Mol. Sci.* 18 (2017) 1586.
- [2] N.S. Nicholas, B. Apollonio, A.G. Ramsay, Tumor microenvironment (TME)-driven immune suppression in B cell malignancy, *BBA-Mol. Cell. Res.* 1863 (2016) 471–482.
- [3] J. Park, D.-H. Kim, H.-N. Kim, C.J. Wang, M.K. Kwak, E. Hur, K.-Y. Suh, S.S. An, A. Levchenko, Directed migration of cancer cells guided by the graded texture of the underlying matrix, *Nat. Mater.* 15 (2016) 792.
- [4] M. Romero-López, A.L. Trinh, A. Sobrino, M.M. Hatch, M.T. Keating, C. Fimbres, D.E. Lewis, P.D. Gershon, E.L. Botvinick, M. Digman, Recapitulating the human tumor microenvironment: colon tumor-derived extracellular matrix promotes angiogenesis and tumor cell growth, *Biomaterials* 116 (2017) 118–129.
- [5] J.-W. Shin, D.J. Mooney, Extracellular matrix stiffness causes systematic variations in proliferation and chemosensitivity in myeloid leukemias, *Proc. Natl. Acad. Sci.* 113 (2016) 12126–12131.
- [6] J.J. Northey, L. Przybyla, V.M. Weaver, Tissue force programs cell fate and tumor aggression, *Cancer Discov.* 7 (2017) 1224–1237.
- [7] L. Kass, J.T. Erler, M. Dembo, V.M. Weaver, Mammary epithelial cell: influence of extracellular matrix composition and organization during development and tumorigenesis, *Int. J. Biochem. Cell Biol.* 39 (2007) 1987–1994.
- [8] J.M. Muncie, V.M. Weaver, The physical and biochemical properties of the extracellular matrix regulate cell fate, *Curr. Top. Dev. Biol.* 130 (2018) 1–37.
- [9] J.M. Northcott, I.S. Dean, J.K. Mouw, V.M. Weaver, Feeling stress: the mechanics of cancer progression and aggression, *Front. Cell Dev. Biol.* 6 (2018) 17.
- [10] C.E. Barcus, E.C. Holt, P.J. Keely, K.W. Eliceiri, L.A. Schuler, Dense collagen-I matrices enhance pro-tumorigenic estrogen-prolactin crosstalk in MCF-7 and T47D breast cancer cells, *PLoS One* 10 (2015) e0116891.
- [11] C.E. Barcus, K.A. O'Leary, J.L. Brockman, D.E. Rugowski, Y. Liu, N. Garcia, M. Yu, P.J. Keely, K.W. Eliceiri, L.A. Schuler, Elevated collagen-I augments tumor progressive signals, intravasation and metastasis of prolactin-induced estrogen receptor alpha positive mammary tumor cells, *Breast Cancer Res.* 19 (2017) 9.
- [12] H.M. Brechbuhl, J. Finlay-Schultz, T.M. Yamamoto, A.E. Gillen, D.M. Cittelty, A.-C. Tan, S.B. Sams, M.M. Pillai, A.D. Elias, W.A. Robinson, Fibroblast subtypes regulate responsiveness of luminal breast cancer to estrogen, *Clin. Cancer Res.* 23 (2017) 1710–1721.
- [13] C. Zhang, D. Samanta, H. Lu, J.W. Bullen, H. Zhang, I. Chen, X. He, G.L. Semenza, Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m6A-demethylation of NANOG mRNA, *Proc. Natl. Acad. Sci.* 113 (2016) E2047–E2056.
- [14] R.J. Seager, C. Hajal, F. Spill, R.D. Kamm, M.H. Zaman, Dynamic interplay between tumour, stroma and immune system can drive or prevent tumour progression, *Convergent Sci. Phys. Oncol.* 3 (2017) 034002.
- [15] M.U. Mushtaq, A. Papadas, A. Pagenkopf, E. Flietner, Z. Morrow, S.G. Chaudhary, F. Asimakopoulou, Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers, *J. Immunother. Cancer* 6 (2018) 65.
- [16] I.J. Cohen, R. Blasberg, Impact of the tumor microenvironment on tumor-infiltrating lymphocytes: focus on breast cancer, *Breast Cancer Basic Clin. Res.* 11 (2017) 1178223417731565.
- [17] D.S. Chen, I. Mellman, Oncology meets immunology: the cancer-immunity cycle, *Immunity* 39 (2013) 1–10.
- [18] M. Huse, Mechanical forces in the immune system, *Nat. Rev. Immunol.* 17 (2017) 679.
- [19] R. Hallmann, X. Zhang, J. Di Russo, L. Li, J. Song, M.-J. Hannocks, L. Sorokin, The regulation of immune cell trafficking by the extracellular matrix, *Curr. Opin. Cell Biol.* 36 (2015) 54–61.
- [20] R.A. Soo, S.M. Lim, N.L. Syn, R. Teng, R. Soong, T.S. Mok, B.C. Cho, Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: current controversies and future directions, *Lung Cancer* 115 (2017) 12–20.
- [21] E.A. Akbay, S. Koyama, J. Carretero, A. Altan, J.H. Tchaicha, C.L. Christensen, O.R. Mikse, A.D. Cherniack, E.M. Beauchamp, T.J. Pugh, Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors, *Cancer Discov.* 3 (12) (2013) 1355–1363.
- [22] D. Lv, Z. Hu, L. Lu, H. Lu, X. Xu, Three-dimensional cell culture: a powerful tool in tumor research and drug discovery, *Oncol. Lett.* 14 (2017) 6999–7010.
- [23] T.Y. Tu, Z. Wang, J. Bai, W. Sun, W.K. Peng, R.Y.J. Huang, J.P. Thiery, R.D. Kamm, Rapid prototyping of concave microwells for the formation of 3D multicellular cancer aggregates for drug screening, *Adv. Healthc. Mater.* 3 (2014) 609–616.
- [24] J.E. Ekert, K. Johnson, B. Strake, J. Pardinas, S. Jarantow, R. Perkinson, D.C. Colter, Three-dimensional lung tumor microenvironment modulates therapeutic compound responsiveness in vitro—implication for drug development, *PLoS One* 9 (2014) e92248.
- [25] T. Ishiguro, H. Ohata, A. Sato, K. Yamawaki, T. Enomoto, K. Okamoto, Tumor-derived spheroids: relevance to cancer stem cells and clinical applications, *Cancer Sci.* 108 (2017) 283–289.
- [26] D.S. Reynolds, K.M. Tevis, W.A. Blessing, Y.L. Colson, M.H. Zaman, M.W. Grinstaff, Breast cancer spheroids reveal a differential cancer stem cell response to chemotherapeutic treatment, *Sci. Rep.* 7 (2017) 10382.
- [27] M.S. Yousafzai, G. Coccano, S. Bonin, J. Niemela, G. Scoles, D. Cojoc, Investigating the effect of cell substrate on cancer cell stiffness by optical tweezers, *J. Biomech.* 60 (2017) 266–269.

- [28] M. Prager-Khoutorsky, A. Lichtenstein, R. Krishnan, K. Rajendran, A. Mayo, Z. Kam, B. Geiger, A.D. Bershadsky, Fibroblast polarization is a matrix-rigidity-dependent process controlled by focal adhesion mechanosensing, *Nat. Cell Biol.* 13 (2011) 1457.
- [29] F. Rico, P. Roca-Cusachs, N. Gavara, R. Farré, M. Rotger, D. Navajas, Probing mechanical properties of living cells by atomic force microscopy with blunted pyramidal cantilever tips, *Phys. Rev. E* 72 (2005) 021914.
- [30] S. Azadi, M. Tafazzoli-Shadpour, R. Omidvar, L. Moradi, M. Habibi-Anbouhi, Epidermal growth factor receptor targeting alters gene expression and restores the adhesion function of cancerous cells as measured by single cell force spectroscopy, *Mol. Cell. Biochem.* 423 (2016) 129–139.
- [31] A. Cavazzoni, R.R. Alfieri, D. Cretella, F. Sacconi, L. Ampollini, M. Galetti, F. Quaini, G. Graiani, D. Madeddu, P. Mozzoni, Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines, *Mol. Cancer* 11 (2012) 91.
- [32] A. Kang, H.I. Seo, B.G. Chung, S.-H. Lee, Concave microwell array-mediated three-dimensional tumor model for screening anticancer drug-loaded nanoparticles, *Nanomedicine* 11 (2015) 1153–1161.
- [33] Y. Jo, N. Choi, H.N. Kim, J. Choi, Probing characteristics of cancer cells cultured on engineered platforms simulating different microenvironments, *Artif. Cells Nanomedicine Biotechnol.* 46 (2018) 1–10.
- [34] Y. Wang, M.H. Kim, S.R. Tabaei, J.H. Park, K. Na, S. Chung, V.P. Zhdanov, N.-J. Cho, Spheroid formation of hepatocarcinoma cells in microwells: experiments and Monte Carlo simulations, *PLoS One* 11 (2016) e0161915.
- [35] C.T. Rueden, J. Schindelin, M.C. Hiner, B.E. DeZonia, A.E. Walter, E.T. Arena, K.W. Eliceiri, ImageJ2: ImageJ for the next generation of scientific image data, *BMC Bioinf.* 18 (2017) 529.
- [36] C. Rianna, M. Radmacher, Influence of microenvironment topography and stiffness on the mechanics and motility of normal and cancer renal cells, *Nanoscale* 9 (2017) 11222–11230.
- [37] J.R. Staunton, W. Vieira, K.L. Fung, R. Lake, A. Devine, K. Tanner, Mechanical properties of the tumor stromal microenvironment probed in vitro and ex vivo by in situ-calibrated optical trap-based active microrheology, *Cell. Mol. Bioeng.* 9 (2016) 398–417.
- [38] E.-M. Rom-Jurek, N. Kirchhammer, P. Ugocsai, O. Ortmann, A.K. Wege, G. Brockhoff, Regulation of programmed death ligand 1 (PD-L1) expression in breast cancer cell lines in vitro and in immunodeficient and humanized tumor mice, *Int. J. Mol. Sci.* 19 (2018) 563.
- [39] Y. Wang, H. Wang, H. Yao, C. Li, J.-Y. Fang, J. Xu, Regulation of PD-L1: emerging routes for targeting tumor immune evasion, *Frontiers in Pharmacology*, 9, (2018).
- [40] F.L. Ricklefs, Q. Alayo, H. Krenzelin, A.B. Mahmoud, M.C. Speranza, H. Nakashima, J.L. Hayes, K. Lee, L. Balaj, C. Passaro, Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles, *Sci. Adv.* 4 (3) (2018) eaar2766.
- [41] H. Soliman, F. Khalil, S. Antonia, PD-L1 expression is increased in a subset of basal type breast cancer cells, *PLoS One* 9 (2014) e88557.
- [42] S. Kim, J. Koh, D. Kwon, B. Keam, H. Go, Y.A. Kim, Y.K. Jeon, D.H. Chung, Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas, *Eur. J. Cancer* 75 (2017) 141–149.
- [43] J. Raczowska, S. Prauzner-Bechcicki, Discrimination between HCV29 and T24 by controlled proliferation of cells co-cultured on substrates with different elasticity, *J. Mech. Behav. Biomed. Mater.* 88 (2018) 217–222.
- [44] S. Prauzner-Bechcicki, J. Raczowska, E. Madej, J. Pabijan, J. Lukes, J. Sepitka, J. Rysz, K. Awiuk, A. Bernasik, A. Budkowski, PDMS substrate stiffness affects the morphology and growth profiles of cancerous prostate and melanoma cells, *J. Mech. Behav. Biomed. Mater.* 41 (2015) 13–22.
- [45] V. Shukla, N. Higuera-Castro, P. Nana-Sinkam, S. Ghadiali, Substrate stiffness modulates lung cancer cell migration but not epithelial to mesenchymal transition, *J. Biomed. Mater. Res. A* 104 (2016) 1182–1193.
- [46] A. Ansardamavandi, M. Tafazzoli-Shadpour, M.A. Shokrgozar, Behavioral re-modeling of normal and cancerous epithelial cell lines with differing invasion potential induced by substrate elastic modulus, *Cell Adhes. Migr.* 12 (2018) 472–488.
- [47] J.G. Goetz, S. Minguet, I. Navarro-Lérida, J.J. Lazzano, R. Samaniego, E. Calvo, M. Tello, T. Osteso-Ibáñez, T. Pellinen, A. Echarri, Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis, *Cell* 146 (2011) 148–163.
- [48] A. Miyazawa, S. Ito, S. Asano, I. Tanaka, M. Sato, M. Kondo, Y. Hasegawa, Regulation of PD-L1 expression by matrix stiffness in lung cancer cells, *Biochem. Biophys. Res. Commun.* 495 (2018) 2344–2349.
- [49] K. Takada, G. Toyokawa, T. Tagawa, K. Kohashi, M. Shimokawa, T. Akamine, S. Takamori, F. Hirai, F. Shoji, T. Okamoto, PD-L1 expression according to the EGFR status in primary lung adenocarcinoma, *Lung Cancer* 116 (2018) 1–6.
- [50] P. Dong, Y. Xiong, J. Yue, S.J. Hanley, H. Watari, Tumor-intrinsic PD-L1 signaling in cancer initiation, development and treatment: beyond immune evasion, *Frontiers in oncology* 8 (2018).
- [51] E. Kumaraswamy, K.L. Wendt, L.A. Augustine, S.R. Stecklein, E.C. Sibala, D. Li, S. Gunewardena, R.A. Jensen, BRCA1 regulation of epidermal growth factor receptor (EGFR) expression in human breast cancer cells involves microRNA-146a and is critical for its tumor suppressor function, *Oncogene* 34 (2015) 4333.
- [52] T. Tanei, D.S. Choi, A.A. Rodriguez, D.H. Liang, L. Dobrolecki, M. Ghosh, M.D. Landis, J.C. Chang, Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells, *Breast Cancer Res.* 18 (2016) 6.
- [53] N. Zhang, Y. Zeng, W. Du, J. Zhu, D. Shen, Z. Liu, J.-A. Huang, The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer, *Int. J. Oncol.* 49 (2016) 1360–1368.
- [54] T. Sasada, K. Azuma, J. Ohtake, Y. Fujimoto, Immune responses to epidermal growth factor receptor (EGFR) and their application for cancer treatment, *Front. Pharmacol.* 7 (2016) 405.
- [55] I. Moya-Horno, S. Viteri, N. Karachaliou, R. Rosell, Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC), *Ther. Adv. Med. Oncol.* 10 (2018) 1758834017745012.
- [56] S. Peng, Q. Li, W. Wang, Acquired resistance to EGFR-TKI upregulates the expression of PD-L1 and promotes immune escape in lung cancer, *AACR* (2017).
- [57] W. Jeon, B. Lim, S. Han, W. Kwack, B. Chang, H. Choi, Y. Kim, C. Choi, M. Park, J.-H. Yoo, Positive PD-L1 expression is associated with unfavorable clinical outcome in EGFR-mutated lung adenocarcinomas treated with EGFR-TKIs, D110. Lung Cancer: Optimizing Screening, Diagnosis, and Treatment, American Thoracic Society, Place Published, 2019, pp. A7291-A7291.
- [58] A. Alsuliman, D. Colak, O. Al-Harazi, H. Fitwi, A. Tulbah, T. Al-Tweigeri, M. Al-Alwan, H. Ghebeh, Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells, *Mol. Cancer* 14 (2015) 149.
- [59] T.M. Malta, A. Sokolov, A.J. Gentles, T. Burzykowski, L. Poisson, J.N. Weinstein, B. Kamińska, J. Huelsken, L. Omberg, O. Gevaert, Machine learning identifies stemness features associated with oncogenic dedifferentiation, *Cell* 173 (2018) 338–354 e315.
- [60] M.Z. Noman, B. Janji, A. Abdou, M. Hasmim, S. Terry, T.Z. Tan, F. Mami-Chouaib, J.P. Thiery, S. Chouaib, The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200, *Oncoimmunology* 6 (2017) e1263412.
- [61] S. Almozayn, D. Colak, F. Mansour, A. Alaiya, O. Al-Harazi, A. Qattan, F. Al-Mohanna, M. Al-Alwan, H. Ghebeh, PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation, *Int. J. Cancer* 141 (2017) 1402–1412.
- [62] Y. You, Q. Zheng, Y. Dong, X. Xie, Y. Wang, S. Wu, L. Zhang, Y. Wang, T. Xue, Z. Wang, Matrix stiffness-mediated effects on stemness characteristics occurring in HCC cells, *Oncotarget* 7 (2016) 32221.
- [63] E.L. Abhold, A. Kiang, E. Rahimy, S.Z. Kuo, J. Wang-Rodriguez, J.P. Lopez, K.J. Blair, M.A. Yu, M. Haas, K.T. Brumund, EGFR kinase promotes acquisition of stem cell-like properties: a potential therapeutic target in head and neck squamous cell carcinoma stem cells, *PLoS One* 7 (2012) e32459.
- [64] A. Rice, E. Cortes, D. Lachowski, B. Cheung, S. Karim, J. Morton, A. Del Rio Hernandez, Matrix stiffness induces epithelial–mesenchymal transition and promotes chemoresistance in pancreatic cancer cells, *Oncogenesis* 6 (2017) e352.
- [65] C. Chen, Y. Wei, M. Hummel, T.K. Hoffmann, M. Gross, A.M. Kaufmann, A.E. Albers, Evidence for epithelial–mesenchymal transition in cancer stem cells of head and neck squamous cell carcinoma, *PLoS One* 6 (2011) e16466.
- [66] A.S. Piotrowski-Daspi, J. Tien, C.M. Nelson, Interstitial fluid pressure regulates collective invasion in engineered human breast tumors via Snail, vimentin, and E-cadherin, *Integr. Biol.* 8 (2016) 319–331.
- [67] C.L. Ventola, Cancer immunotherapy, part 3: challenges and future trends, *Pharm. Ther.* 42 (2017) 514.